Share Name Share Symbol Market Type Share ISIN Share Description
Vernalis LSE:VER London Ordinary Share GB00B3Y5L754 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  +0.00p +0.00% 6.17p 0 01:00:00
Bid Price Offer Price High Price Low Price Open Price
0.00p 0.00p - - -
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 12.03 -15.30 -3.20 32.5

Vernalis (VER) Latest News

More Vernalis News
Vernalis Takeover Rumours

Vernalis (VER) Share Charts

1 Year Vernalis Chart

1 Year Vernalis Chart

1 Month Vernalis Chart

1 Month Vernalis Chart

Intraday Vernalis Chart

Intraday Vernalis Chart

Vernalis (VER) Discussions and Chat

Vernalis Forums and Chat

Date Time Title Posts
18/10/201812:57VERNALIS - time to buy?2,092
24/10/201019:57VERNALIS - 500p by December 2010?465
15/9/200917:32Vernalis (VER): Charts and discussion thread38
15/9/200917:31VERNALIS *** UNDERVALUED***1
15/9/200916:38Vernalis - short this junk to 40p?23

Add a New Thread

Vernalis (VER) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Vernalis trades in real-time

Vernalis (VER) Top Chat Posts

qs99: share price is motoring without the ramping Cudmore give it a rest mate! Graph says it all...being plugged on Twitter at the moment as well....DYOR all....i'll check back in after lunch to see how this is faring. TAP is the other momentum play by the way DYOR
compoundinge: Interesting inference... assuming that might be the case. If issue 52,508,700 new shares, would that dilute and reduce Verona's share price quite a bit?
djrhs: Why is the share price going up?
chrisdgb: Come on baby, let us have the 'statement re share price movement......'
joeblogg2: wish I knew but some sort of break up or reverse takeover will be only way to extract value and return for shareholders since decimation of share price!!!!
timbo003: Verona reported positive phase IIB results for RPL554 this morning. With Vernalis due very significant milestone and royalty payments if and when RPL554 is approved, it further underpins the estimated sum of the parts valuation of VER which is considerably more than reflected in the current share price(see posts above)
timbo003: I suspect by end of September this year, the share price will be significantly above 3p per share (3p corresponds to a market capitalisation of around £15m). Reasoning as follows: The old management will have departed; the US business will have gone; on a sum of the parts basis for the remaining business a market cap of £15m looks way too cheap. Some more detailed thoughts below: The Vernalis cash pile was £44m at end of Jan 2018 Historic cash burn for year to June 2017 was £21m/year (see annual report below) and £17m for 7 months to Jan 31st (see link above) Direct promotion of the US cough product (Tuzistra) ceased beginning of March and all US staff will go mid May, there are likely to be some significant closure costs (early lease and contract terminations etc), so cash burn between Jan 31st 2018 and September 2018 is difficult to estimate, but perhaps £30m (worst case) which would leave a £14M cash pile. There is a chance (albeit small) that they could end up selling Tuzistra for a cash sum, or licence it out. They may also go for compensation from their development partner (Tris), for failing to fulfil their obligations on the other joint development projects. Once the US business has gone, the remaining UK business will still have some valuable assets (see annual report for more details). One of the more valuable assets is their stake in RPL554 (which is currently being developed by Verona Pharma) where it is possible to make a reasonable guestimate at the value: Assuming RPL554 is launched during 2020 or 2021 in the US, it will be more or less off patent, yet Vernalis will still recieve a £5m up front payment on first approval, 25% of any sub licence revenue and a 3% royalty of Verona’s sales revenue for 10 years post launch (in each market), this is despite the fact that the Vernalis composition of matter patent will expire in 2020 or thereabouts. From the Verona Pharma Aim admission document Vernalis Royalty Payments (from Aim admission document p67 - 68) Even if you assume that Verona only ever launch RPL554 in the USA in nebulised format for Emergency Room use only and at home use after discharge (to minimise chances of re-admission), gross revenues could easily average £200m/year, implying royalties to Vernalis of £60M over a 10 year period. A more likely scenario is that once the nebulised format has become established, Verona would subsequently launch in dpi and mdi formats, which are much larger opportunities, they would also roll out the products to Europe and other developed markets. There will be further value in the other out-licencing assets (see below): The one with most potential value is probably CPI-444 which is out-licenced to Corvus (Clinical stage, Nasdaq quoted Biopharma, market cap circa $300m) for which Vernalis are due to receive development milestone payments and royalties on sales. Corvus are developing CPI-444 with Genentech (Roche) and as the lead drug in their development portfolio, it probably has a realistic chance of progressing further. There is also continuing royalty income for Frovatriptan (circa £2-3m annually) and a small research division which is mainly funded by collaborators on a fee for service basis, which currently benefits from occasional milestone payments and could eventually benefit from product royalties, should any of the current 6 collaborations lead to marketed products.
yasx: Chuckle chuckle. ------------------------- romeike23 Feb '17 - 12:13 - 1562 of 1777 I doubt there is more to fall, I expect the share price to gradually recover to same level as before the results, about 32p. The results raised more questions that answers as is so common on AIM but the company is in a decent financial position and has everything to play for still.
romeike: I recently reduced my holding here by over 60% as the opportunity arose to swap out the funds into Shire, with its share price severely down for no good reason it makes a lot of sense to do so - far more certainty of a recovery and profits at Shire than here. And CEO Flemming O is leagues ahead of this no hoper Ian Garland at Vernalis. Looks very much like Vernalis strategy is hostage to its partner Tris, with no control over what looks like an increasingly chaotic situation. Can only hope Vernalis is applying pressure but months on and still no word of progress. Strategy making less and less sense with ongoing cash burn at $20m but revenues just a few million, how can this ever make sense without more products hitting the market in a reasonable time.
bones698: fund raising coming judging by the lack of news and share price fall just like agl and nano . Expect it to level off jut above the issue price imo . So far looks like it could be at 8p or possibly 5p . Usual share price reaction when the company goes to the city asking for money no other real explanation I can see
Vernalis share price data is direct from the London Stock Exchange
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190522 16:37:28